Entolimod

About Tivic

Tivic Health is a biotechnology company transitioning into a strategic biopharma player with a late-stage, host-protection immunotherapy platform. Its core technology, the TLR5 agonist Entolimod, is being developed as a military countermeasure for Acute Radiation Syndrome and has potential applications in oncology supportive care (e.g., Neutropenia) and chronic diseases. The company vertically integrates its R&D with a wholly-owned CDMO subsidiary, Velocity Bioworks, providing manufacturing control and a secondary revenue stream while de-risking its pipeline development.

About Tivic

Tivic Health is a biotechnology company transitioning into a strategic biopharma player with a late-stage, host-protection immunotherapy platform. Its core technology, the TLR5 agonist Entolimod, is being developed as a military countermeasure for Acute Radiation Syndrome and has potential applications in oncology supportive care (e.g., Neutropenia) and chronic diseases. The company vertically integrates its R&D with a wholly-owned CDMO subsidiary, Velocity Bioworks, providing manufacturing control and a secondary revenue stream while de-risking its pipeline development.

About Tivic

Tivic Health is a biotechnology company transitioning into a strategic biopharma player with a late-stage, host-protection immunotherapy platform. Its core technology, the TLR5 agonist Entolimod, is being developed as a military countermeasure for Acute Radiation Syndrome and has potential applications in oncology supportive care (e.g., Neutropenia) and chronic diseases. The company vertically integrates its R&D with a wholly-owned CDMO subsidiary, Velocity Bioworks, providing manufacturing control and a secondary revenue stream while de-risking its pipeline development.

Therapeutic Areas

Other Acute Radiation Syndrome (ARS) Drugs